Hikma Pharmaceuticals (Hikma Pharmaceuticals) EV-to-EBITDA

: 10.79 (As of Today)

View and export this data going back to 2009. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hikma Pharmaceuticals's enterprise value is $5,954 Mil. Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $552 Mil. Therefore, Hikma Pharmaceuticals's EV-to-EBITDA for today is 10.79.

The historical rank and industry rank for Hikma Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

HKMPY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.54 Med: 12.51 Max: 20.15
Current: 10.91

During the past 13 years, the highest EV-to-EBITDA of Hikma Pharmaceuticals was 20.15. The lowest was 5.54. And the median was 12.51.

HKMPY's EV-to-EBITDA is ranked better than
60.45% of 708 companies
in the Drug Manufacturers industry
Industry Median: 13.88 vs HKMPY: 10.91

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Hikma Pharmaceuticals's stock price is $46.50. Hikma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.700. Therefore, Hikma Pharmaceuticals's PE Ratio for today is 27.35.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Hikma Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Hikma Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

10.23

11.91

9.73

10.65

10.83

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															9.73	-	10.65	-	10.83

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's EV-to-EBITDA falls into.

Hikma Pharmaceuticals EV-to-EBITDA Calculation

Hikma Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	5953.757	/	552
	=	10.79

Hikma Pharmaceuticals's current Enterprise Value is $5,954 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $552 Mil.

Hikma Pharmaceuticals (OTCPK:HKMPY) EV-to-EBITDA Explanation

Hikma Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	46.50	/	1.700
	=	27.35

Hikma Pharmaceuticals's share price for today is $46.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.700.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Hikma Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals (Hikma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPY) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

HKMPF:USA HIKl:UK HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.